Form 4: Hoth Therapeutics CEO Robb Knie Acquires 100,000 Options
SEC Form 4 Filing
Hoth Therapeutics CEO Robb Knie reports the acquisition of 100,000 options in the company, vesting immediately.
Summary
- Robb Knie, CEO and President of Hoth Therapeutics, acquired a total of 100,000 options on January 14, 2025.
- 93,000 options were issued under the 2018 Equity Incentive Plan, and 7,000 options were issued under the Amended and Restated 2022 Equity Incentive Plan.
- The exercise price for all options is $1.55.
- The options vested in full upon grant and expire on January 14, 2035.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The granting of options to the CEO is a routine event, but it can signal confidence in the company's future.
Positives
- The CEO's acquisition of options could be seen as a positive signal, indicating confidence in the company's future performance.
Industry Context
This type of transaction is common for executives in publicly traded companies as part of their compensation packages, aligning their interests with those of shareholders.
Stakeholder Impact
- The acquisition of options by the CEO could positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 01/14/2025 | Date of options transaction |
| 01/14/2025 | Options become exercisable |
| 01/14/2035 | Options expiration date |
| 01/15/2025 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.